David Thompson
Corporate Officer/Principal presso INOZYME PHARMA, INC.
Posizioni attive di David Thompson
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| INOZYME PHARMA, INC. | Corporate Officer/Principal | 01/07/2021 | - |
Storia della carriera di David Thompson
Precedenti posizioni note di David Thompson
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| INOZYME PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01/04/2018 | 13/10/2020 |
Azure Biotech, Inc.
 Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Founder | - | - |
| President | - | - |
Formazione di David Thompson
| University of Connecticut | Doctorate Degree |
| The University of Montana | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Graduate Degree | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Settori
| Consumer Services | 3 |
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Azure Biotech, Inc.
Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Health Technology |
- Borsa valori
- Insiders
- David Thompson
- Esperienza
